Frazier Life Sciences updates Arcutis Biotherapeutics stake

TL;DR

Frazier Life Sciences just updated their Arcutis Biotherapeutics filing. Watch for changes.

AI Summary

Frazier Life Sciences VIII, L.P. and its affiliates, including James N. Topper and Patrick J. Heron, have amended their Schedule 13D filing regarding Arcutis Biotherapeutics, Inc. as of March 6, 2024. The filing indicates a change in their beneficial ownership, though specific share counts and dollar amounts are not detailed in this excerpt. This amendment signifies an update to their holdings and potentially their investment strategy concerning Arcutis Biotherapeutics.

Why It Matters

This filing indicates a change in significant ownership for Arcutis Biotherapeutics, which could signal shifts in the company's strategic direction or market perception.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings by significant holders can indicate changes in investment strategy or potential activism, warranting close monitoring.

Key Players & Entities

• Frazier Life Sciences VIII, L.P. (company) — Filing entity
• Arcutis Biotherapeutics, Inc. (company) — Subject company
• James N. Topper (person) — Group member of filing entity
• Patrick J. Heron (person) — Group member of filing entity
• Steve R. Bailey (person) — Contact person for filing entity

FAQ

Key Financial Figures

• $38,112,797 — approximate aggregate purchase price of $38,112,797. Upon closing of the IPO, the shares of
• $17.00 — Stock of the Issuer at the IPO price of $17.00 per share. On May 10, 2021, FLS VIII
• $20.00 — shares of Common Stock of the Issuer at $20.00 per share. On October 24, 2023, FLS V
• $2.50 — shares of Common Stock of the Issuer at $2.50 per share. On March 4, 2024, FLS VIII
• $9.50 — shares of Common Stock of the Issuer at $9.50 per share. FLS VIII holds 8,785,284 s

Filing Documents

• d643419dsc13da.htm (SC 13D/A) — 148KB
• 0001193125-24-060422.txt ( ) — 149KB

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 6, 2024 FRAZIER LIFE SCIENCES VIII, L.P. By FHM Life Sciences VIII, L.P., its general partner By FHM Life Sciences VIII, L.L.C., its general partner By: /s/ Steve R. Bailey Steve R. Bailey, Chief Financial Officer Date: March 6, 2024 FHM LIFE SCIENCES VIII, L.P. By FHM Life Sciences VIII, L.L.C., its general partner By: /s/ Steve R. Bailey Steve R. Bailey, Chief Financial Officer Date: March 6, 2024 FHM LIFE SCIENCES VIII, L.L.C. By: /s/ Steve R. Bailey Steve R. Bailey, Chief Financial Officer Date: March 6, 2024 By: * James N. Topper Date: March 6, 2024 By: * Patrick J. Heron Date: March 6, 2024 *By: /s/ Steve R. Bailey Steve R. Bailey, as Attorney-in-Fact This Schedule 13D was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017. Page 13 Exhibit Index Exhibit A - Agreement regarding filing of joint Schedule 13D (incorporated by reference to Exhibit A to the Schedule 13D filed by the Reporting Persons with the Commission on February 7, 2020). Exhibit B - Form of Lock-up Agreement (incorporated by reference to Annex I to that certain Underwriting Agreement between the Issuer and the Underwriters (as defined therein) filed as Exhibit 1.1 to the Issuers Current Report on Form 8-K filed with the Commission on March 4, 2024). Exhibit C - Amended and Restated Investors Rights Agreement (incorporated by reference to Exhibit 4.2 to the Issuers Registration Statement on Form S-1 filed with the Commission on January 6, 2020). Page 14

View Full Filing

View this SC 13D/A filing on SEC EDGAR